A Phase 2 interventional study of Febuxostat IR and Febuxostat XR in Gout and Moderate Renal Impairment, sponsored by Takeda. Completed at 89 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-03.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.
Among the 29 studies testing febuxostat in Gout, this one is the 11th largest by enrollment, is one of 4 that started in 2014, is one of 9 in phase 2, and was the 19th registered.
347 studies on the registry are indexed under Gout; 49 are open to participants now.
Browse Gout studies →1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:
Haiphong University of Medicine and Pharmacy
Healthy volunteers
Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 189 is above the median of 83 across 286 interventional studies indexed under Gout.
Median enrollment 109 across the 29 interventional studies. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 29 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Gout by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Gout by Takeda, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2014, is one of 5 in phase 2, and was the 12th registered.
Takeda’s Gout studies by the year they started, since 2001.
1 of the studies testing febuxostat in Gout that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07369622Haiphong University of Medicine and PharmacyHLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness | 2027-06-20 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing febuxostat in Gout, from their registry updates:
Among Takeda’s 15 in Gout:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in gout participants with moderate renal impairment.
The drug being tested in this study is called febuxostat. Febuxostat is being tested to decrease and maintain serum urate in people who have gout with moderate renal impairment. This study will look at serum urate levels in people who take febuxostat extended release (XR) capsules compared to febuxostat immediate release (IR) capsules and placebo.
The study will enroll approximately 200 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the five treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
All participants will be asked to take one capsule at the same time each day throughout the study, and will be asked to call an interactive voice response system any time they are having a gout flare up. In addition to study medication, participants will also take 0.6 mg of colchicine every other day or naproxen 250 mg twice a day with lansoprazole 15 mg once a day to prevent gout flare ups.
This multi-center trial will be conducted in the United States. The overall time to participate in this study is up to approximately 4 months and participants will make up to 7 visits to the clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has a history or presence of gout defined as having one or more of the American Rheumatism Association (ARA) criteria for the diagnosis of gout:
i. more than one attack of acute arthritis, ii. maximum inflammation developed within 1 day, iii. monoarticular arthritis, iv. redness observed over joints, v. first metatarsophalangeal joint painful or swollen, vi. unilateral first metatarsophalangeal joint attack, vii. unilateral tarsal joint attack, viii. tophus (proven or suspected), ix. Hyperuricemia, x. asymmetric swelling within a joint on x-ray, xi. subcortical cysts without erosions on x-ray, xii. joint fluid culture negative for organisms during attack.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
Drug: Febuxostat IR · Drug: Colchicine · Drug: Naproxen · Drug: Lansoprazole
Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
Drug: Febuxostat IR · Drug: Colchicine · Drug: Naproxen · Drug: Lansoprazole
Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
Drug: Febuxostat XR · Drug: Colchicine · Drug: Naproxen · Drug: Lansoprazole
Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
Drug: Febuxostat XR · Drug: Colchicine · Drug: Naproxen · Drug: Lansoprazole
Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
Drug: Febuxostat placebo · Drug: Colchicine · Drug: Naproxen · Drug: Lansoprazole
Febuxostat IR over-encapsulated tablets
Also known as: Uloric
Febuxostat over-encapsulated capsules
Febuxostat IR and XR placebo-matching capsules
Colchicine tablets
Naproxen tablets
Lansoprazole capsules
Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3
Time frame: Month 3
Percentage of Participants With at Least One Gout Flare Requiring Treatment
A participant was considered to have a gout flare if the following criteria were met: Participant-reported acute particular pain typical of a gout attack that was deemed by participant and/or investigator to require treatment and was treated with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids, Participant experienced at least 3 or more of: 1) Joint swelling, 2) Redness, 3) Tenderness, 4) Pain, Participant experienced at least one or more of: 1) Rapid onset of pain, 2) Decreased range of motion, 3) Joint warmth, 4) Other symptoms similar to a prior gout flare.
Time frame: Baseline to Month 3
Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3
Time frame: Month 3
Participants took part in the study at 65 investigative sites in the United States from 5 May 2014 to 23 October 2015.
| Milestone | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg |
|---|---|---|---|---|---|
| Started | 38 | 37 | 39 | 37 | 38 |
| Completed | 33 | 31 | 34 | 31 | 31 |
| Not completed | 5 | 6 | 5 | 6 | 7 |
| Withdrew: Pretreatment event/adverse event | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Major protocol deviation | 1 | 2 | 0 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Voluntary withdrawal | 3 | 3 | 1 | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdraw from study drug, gout flare | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other miscellaneous reasons | 0 | 0 | 2 | 1 | 1 |
| percentage of participants | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg |
|---|---|---|---|---|---|
| Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3 | 0 | 13.5 | 35.9 | 40.5 | 44.7 |
A participant was considered to have a gout flare if the following criteria were met: Participant-reported acute particular pain typical of a gout attack that was deemed by participant and/or investigator to require treatment and was treated with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids, Participant experienced at least 3 or more of: 1) Joint swelling, 2) Redness, 3) Tenderness, 4) Pain, Participant experienced at least one or more of: 1) Rapid onset of pain, 2) Decreased range of motion, 3) Joint warmth, 4) Other symptoms similar to a prior gout flare.
| percentage of participants | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Gout Flare Requiring Treatment | 10.5 | 40.5 | 23.1 | 37.8 | 42.1 |
| percentage of participants | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg |
|---|---|---|---|---|---|
| Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3 | 0 | 32.4 | 53.8 | 59.5 | 55.3 |
Collected over First dose of double-blind study drug to 30 days past last dose of double-blind study drug (Up to 4 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/38 (0%) | 3/38 (7.9%) |
| Febuxostat IR 40 mg | — | 1/37 (2.7%) | 5/37 (13.5%) |
| Febuxostat XR 40 mg | — | 1/39 (2.6%) | 4/39 (10.3%) |
| Febuxostat IR 80 mg | — | 0/37 (0%) | 1/37 (2.7%) |
| Febuxostat XR 80 mg | — | 4/38 (10.5%) | 3/38 (7.9%) |
| Event | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg |
|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 0/38 | 1/37 | 0/39 | 0/37 | 0/38 |
| Acute kidney injuryRenal and urinary disorders | 0/38 | 1/37 | 0/39 | 0/37 | 0/38 |
| Coronary artery diseaseCardiac disorders | 0/38 | 0/37 | 0/39 | 0/37 | 1/38 |
| Sinus node dusfunctionCardiac disorders | 0/38 | 0/37 | 0/39 | 0/37 | 1/38 |
| Cardiac arrestCardiac disorders | 0/38 | 0/37 | 0/39 | 0/37 | 1/38 |
| GangreneInfections and infestations | 0/38 | 0/37 | 0/39 | 0/37 | 1/38 |
| HypertensionVascular disorders | 0/38 | 0/37 | 0/39 | 0/37 | 1/38 |
| CholelithiasisHepatobiliary disorders | 0/38 | 0/37 | 1/39 | 0/37 | 0/38 |
| Event | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg |
|---|---|---|---|---|---|
| HypertensionVascular disorders | 1/38 | 1/37 | 0/39 | 1/37 | 3/38 |
| DiarrhoeaGastrointestinal disorders | 0/38 | 2/37 | 0/39 | 0/37 | 0/38 |
| Urinary tract infectionInfections and infestations | 0/38 | 2/37 | 0/39 | 0/37 | 0/38 |
| Renal failureRenal and urinary disorders | 2/38 | 0/37 | 0/39 | 0/37 | 0/38 |
| PalpitationsCardiac disorders | 0/38 | 0/37 | 2/39 | 0/37 | 0/38 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/38 | 0/37 | 2/39 | 0/37 | 0/38 |
Full Analysis Set (FAS) included all participants who were randomized and received at least 1 dose of double-blind study medication.
| Age, Continuous(years) | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 64.6 ± 12.78 | 61.3 ± 10.09 | 64.4 ± 11.21 | 63.5 ± 10.33 | 61.4 ± 12.17 | 63.1 ± 11.34 |
| Age, Customized(participants) | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg | Total |
|---|---|---|---|---|---|---|
| < 45 years | 1 | 3 | 1 | 0 | 4 | 9 |
| 45 to < 65 years | 14 | 16 | 15 | 18 | 18 | 81 |
| >= 65 years | 23 | 18 | 23 | 19 | 16 | 99 |
| Age, Customized(participants) | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg | Total |
|---|---|---|---|---|---|---|
| 18 to < 65 years | 15 | 19 | 16 | 18 | 22 | 90 |
| 65 to < 85 years | 21 | 18 | 23 | 19 | 16 | 97 |
| >= 85 years | 2 | 0 | 0 | 0 | 0 | 2 |
| Sex: Female, Male(Participants) | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg | Total |
|---|---|---|---|---|---|---|
| Female | 12 | 12 | 13 | 9 | 9 | 55 |
| Male | 26 | 25 | 26 | 28 | 29 | 134 |
| Race/Ethnicity, Customized(participants) | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg | Total |
|---|---|---|---|---|---|---|
| Asian | 0 | 2 | 1 | 2 | 4 | 9 |
| Black or African American | 4 | 10 | 10 | 12 | 10 | 46 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 | 0 | 4 |
| White | 33 | 24 | 26 | 21 | 22 | 126 |
| Other: Multi-racial | 0 | 1 | 1 | 0 | 2 | 4 |
| Race/Ethnicity, Customized(participants) | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 7 | 7 | 7 | 24 |
| Not Hispanic or Latino | 36 | 36 | 32 | 30 | 31 | 165 |
| Region of Enrollment(participants) | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg | Total |
|---|---|---|---|---|---|---|
| United States | 38 | 37 | 39 | 37 | 38 | 189 |
| Height(cm) | Placebo | Febuxostat IR 40 mg | Febuxostat XR 40 mg | Febuxostat IR 80 mg | Febuxostat XR 80 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 171.5 ± 10.47 | 172.8 ± 10.39 | 171.6 ± 9.99 | 170.7 ± 11.16 | 173.4 ± 9.63 | 172.0 ± 10.27 |
4 further baseline measures are reported on the registry.
The record gives a start of May 2014, a primary completion of Sep 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 1 year 2 months after primary completion. A results delay was requested in Jun 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat